Vytrus Biotech

Vytrus Biotech Equity

The The Equity of Vytrus Biotech (VYT.MC) as of Oct 12, 2026 is 10.31 M EUR. In the previous year, The Equity was 7.29 M EUR — a change of 41.34% (higher).

Equity

10.31 MEUR

YoY

41.34%

Last updated:

In 2025, Vytrus Biotech's equity was 10.31 M EUR, a 41.34% increase from the 7.29 M EUR equity in the previous year.

The Vytrus Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
2.25 M EUR
Jan 1, 2019
3.44 M EUR
Jan 1, 2020
3.61 M EUR
Jan 1, 2021
4.25 M EUR
Jan 1, 2022
4.75 M EUR
Jan 1, 2023
5.29 M EUR
Jan 1, 2024
7.29 M EUR
Jan 1, 2025
10.31 M EUR
The Vytrus Biotech Equity history
YEAREquityYoY
10.31 MEUR+41.34%
7.29 MEUR+37.80%
5.29 MEUR+11.34%
4.75 MEUR+11.83%
4.25 MEUR+17.75%
3.61 MEUR+4.92%
3.44 MEUR+53.15%
2.25 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Vytrus Biotech Stock analysis

What does Vytrus Biotech do? Vytrus Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Vytrus Biotech's Equity

Vytrus Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vytrus Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vytrus Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vytrus Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vytrus Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vytrus Biotech stock

The Equity of Vytrus Biotech is 10.31 M EUR in 2025.

The Equity of Vytrus Biotech changed from 7.29 M EUR to 10.31 M EUR, representing a 41.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Vytrus Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Vytrus Biotech historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Vytrus Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vytrus Biotech